The association between neutrophil gelatinase‐associated lipocalin and clinical outcome in chronic heart failure: results from CORONA*
Authors:
- 16 January 2012
- journal article
- research article
- Published by Wiley in Journal of Internal Medicine
- Vol. 271 (5) , 436-443
Abstract
Abstract. Nymo SH, Ueland T, Askevold ET, Flo TH, Kjekshus J, Hulthe J, Wikstrand J, McMurray J, Van Veldhuisen DJ, Gullestad L, Aukrust P, Yndestad A (Oslo University Hospital Rikshospitalet; University of Oslo; Oslo; Norwegian University of Technology and Science, Trondheim, Norway; Gothenburg University, Gothenburg; AstraZeneca, Mölndal, Sweden; University of Glasgow, UK; and University Medical Center Groningen, University of Groningen, The Netherlands). The association between neutrophil gelatinase‐associated lipocalin and clinical outcome in chronic heart failure: results from CORONA. J Intern Med 2012; 271: 436–443.Objective. To study the prognostic value of neutrophil gelatinase‐associated lipocalin (NGAL) in chronic heart failure (HF) of ischaemic aetiology.Background. Neutrophil gelatinase‐associated lipocalin is a marker of kidney injury as well as matrix degradation and inflammation and has previously been shown to be increased in HF. We investigated whether serum NGAL levels could provide prognostic information in chronic HF.Methods. We assessed NGAL as a predictor of primary outcomes (cardiovascular death, nonfatal stroke and nonfatal myocardial infarction, n = 307) and all‐cause mortality (n = 321), cardiovascular mortality (n = 259) and hospitalization (n = 647) as well as the number of hospitalizations during follow‐up for all (n = 1934) and CV causes (n = 1204) in 1415 patients with chronic HF (≥60 years, New York Heart Association class II–IV, ischaemic systolic HF) in the CORONA population, randomly assigned to 10 mg rosuvastatin or placebo.Results. Multivariate analysis revealed that NGAL added significant information when adjusting for clinical variables, but was no longer significant when further adjusting for apolipoprotein A‐1 (ApoA‐1), glomerular filtration rate (GFR), C‐reactive protein (CRP) and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP). However, belonging to the highest NGAL tertile was associated with more frequent hospitalization, even after adjusting for clinical variables, GFR and ApoA‐1, but not after adjusting for CRP and NT‐proBNP. There was no interaction between rosuvastatin treatment and NGAL.Conclusion. Neutrophil gelatinase‐associated lipocalin added no significant information to NT‐proBNP and GFR in a multivariate model for primary and secondary end‐points.Keywords
This publication has 29 references indexed in Scilit:
- Prognostic Utility of Plasma Neutrophil Gelatinase-Associated Lipocalin in Patients with Acute Heart Failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in Acutely Decompensated Heart Failure (GALLANT) TrialEuropean Journal of Heart Failure, 2011
- Renal Dysfunction Is a Stronger Determinant of Systemic Neutrophil Gelatinase–Associated Lipocalin Levels Than Myocardial Dysfunction in Systolic Heart FailureJournal of Cardiac Failure, 2011
- Extensions of net reclassification improvement calculations to measure usefulness of new biomarkersStatistics in Medicine, 2010
- Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rateHeart, 2010
- Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)Circulation, 2009
- Neutrophil gelatinase-associated lipocalin (NGAL/Lcn2) is upregulated in gastric mucosa infected with Helicobacter pyloriVirchows Archiv, 2009
- Predictors of Fatal and Non-Fatal Outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): Incremental Value of Apolipoprotein A-1, High-Sensitivity C-Reactive Peptide and N-terminal pro B-type Natriuretic PeptideEuropean Journal of Heart Failure, 2009
- The Local and Systemic Inflammatory Transcriptome after Acute Kidney InjuryJournal of the American Society of Nephrology, 2008
- Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected patients: increase during highly active anti-retroviral therapyClinical and Experimental Immunology, 2008
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999